[1] |
李明,顾晋.中国结直肠癌20年来发病模式的变化趋势.中华胃肠外科杂志, 2004, 7(3): 214-217.
|
[2] |
Siegel R, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
|
[3] |
Sauer R, BeckerH, HohenbergerW, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEngl J Med, 2004, 351(17): 1731-1740.
|
[4] |
Rolf S, TorstenL, SusanneM, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. JClin Oncol, 2012, 30(16): 1926-1933.
|
[5] |
Ellen K, CorrieM, IrisD, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 2001, 345(9): 638-646.
|
[6] |
FolkessonJ, BirgissonH, PahlmanL, et al.Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. JClin Oncol, 2005, 23(24): 5644-5650.
|
[7] |
KaratagO, KaratagGY, OzkurtH, et al. The ability of phased-array MRI in preoperative staging of primary rectal cancer: correlation with histopathologicalresults. DiagnInterv Radiol, 2012, 18(1): 20-26.
|
[8] |
Falcone A, RicciS, BrunettiI, et al. Phase III trial of infusionalfluorouracil, leucovorin, oxaliplatin, andirinotecan (FOLFOXIRI) compared with infusionalfluorouracil, leucovorin, andirinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: theGruppoOncologico Nord Ovest. JClin Oncol, 2007, 25(13): 1670-1676.
|
[9] |
蔡月,胡华斌,王文静,等.改良FOLFOXIRI方案在晚期结直肠癌患者一线治疗中的安全性和疗效分析.中华胃肠外科杂志, 2014, 17(11): 1081-1086.
|
[10] |
SunakawaY, FujitaK, Ichikawa W, et al. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1, *1/*6 or *1/*28. Oncology, 2012, 82(4): 242-248.
|
[11] |
UeharaK, HiramatsuK, Maeda, et al. Neoadjuvantoxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol, 2013, 43(10): 964-971.
|
[12] |
SchragD, WeiserMR, GoodmanKA et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. JClin Oncol, 2014, 32(6): 513-518.
|
[13] |
Fernandez-MartosC, EstevanR, SaludA, et al. Neoadjuvant capecitabine, xoliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. JClin Oncol, 2012, 30 (suppl.), Abstract: 3586.
|